0
Letters |

Antiarrhythmic Therapy for Prevention of Implantable Cardioverter Defibrillator ShocksAntiarrhythmic Therapy for Prevention of Implantable Cardioverter Defibrillator Shocks

JAMA. 2006;296(10):1229-1230. doi:10.1001/jama.296.10.1229-a
Text Size: A A A
Published online

AUTHOR INFORMATION

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

ANTIARRHYTHMIC THERAPY FOR PREVENTION OF IMPLANTABLE CARDIOVERTER DEFIBRILLATOR SHOCKS

To the Editor: In their study on the effects of antiarrhythmic drugs for prevention of shocks from implantable cardioverter defibrillators (ICDs), Dr Connolly and colleagues1 classified these shocks as appropriate due to ventricular tachycardia or ventricular fibrillation or inappropriate due to supraventricular tachycardia. However, inappropriate shocks could be from other sources that cannot be suppressed by antiarrhythmic medications,2 and therefore should not be included in analysis. Such shocks occur as a result of oversensing of T waves in patients with hypertrophic cardiomyopathy, oversensing due to fracture of the leads, or electromagnetic interference from a variety of sources. The authors did not mention the number of such shocks and whether they were excluded from the analysis.

They also did not state whether patients with arrhythmic storm (refractory ventricular tachycardia or ventricular fibrillation) were included in the study. Patients who develop arrhythmic storm are typically sicker, require frequent rehospitalization, have lower left ventricular ejection fraction, have overall poorer long-term prognosis, and sometimes require addition of another antiarrhythmic drug, such as procainamide or mexiletine.3 4 These patients frequently have recurrence of arrhythmic storm. Inclusion of such patients in the analysis would dilute the findings of this study.

Financial Disclosures: None reported.

References
Connolly SJ, Dorian P, Roberts RS.  et al.  Comparison of β-blockers, amiodarone plus β-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators.  JAMA. 2006;295165-171
PubMed
Swerdlow CD, Shivkumar K. Implantable cardioverter-defibrillators: clinical aspects. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia, Pa: WB Saunders Co; 2004:988-990
Verma A, Kilicaslan F, Marrouche NF.  et al.  Prevalence, predictors, and mortality significance of the causative arrhythmia in patients with electrical storm.  J Cardiovasc Electrophysiol. 2004;151265-1270
PubMed
Krivan L, Kozak M, Sepsi M, Svobodnik A, Spinar J. Treatment of arrhythmic storm in implantable defibrillator patients [published online ahead of print August 26, 2005].  Med Sci Monit. 2005;11426-429
PubMed

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Connolly SJ, Dorian P, Roberts RS.  et al.  Comparison of β-blockers, amiodarone plus β-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators.  JAMA. 2006;295165-171
PubMed
Swerdlow CD, Shivkumar K. Implantable cardioverter-defibrillators: clinical aspects. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia, Pa: WB Saunders Co; 2004:988-990
Verma A, Kilicaslan F, Marrouche NF.  et al.  Prevalence, predictors, and mortality significance of the causative arrhythmia in patients with electrical storm.  J Cardiovasc Electrophysiol. 2004;151265-1270
PubMed
Krivan L, Kozak M, Sepsi M, Svobodnik A, Spinar J. Treatment of arrhythmic storm in implantable defibrillator patients [published online ahead of print August 26, 2005].  Med Sci Monit. 2005;11426-429
PubMed
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.